MAPLIGHT THERAPEUTICS INC (MPLT) Stock Price & Overview
NASDAQ:MPLT • US56565P1030
Current stock price
The current stock price of MPLT is 27.62 USD. Today MPLT is down by -2.54%. In the past month the price increased by 61.71%.
MPLT Key Statistics
- Market Cap
- 1.172B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.13
- Dividend Yield
- N/A
MPLT Stock Performance
MPLT Stock Chart
MPLT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MPLT.
MPLT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MPLT. No worries on liquidiy or solvency for MPLT as it has an excellent financial health rating, but there are worries on the profitability.
MPLT Earnings
MPLT Forecast & Estimates
11 analysts have analysed MPLT and the average price target is 33.32 USD. This implies a price increase of 20.64% is expected in the next year compared to the current price of 27.62.
MPLT Groups
Sector & Classification
MPLT Financial Highlights
Over the last trailing twelve months MPLT reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS decreased by -39.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.27% | ||
| ROE | -203.52% | ||
| Debt/Equity | 0 |
MPLT Ownership
MPLT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MPLT
Company Profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California and currently employs 109 full-time employees. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
Company Info
IPO: 2025-10-27
MAPLIGHT THERAPEUTICS INC
800 Chesapeake Drive
Redwood City CALIFORNIA US
Employees: 109
Phone: 16508394360
MAPLIGHT THERAPEUTICS INC / MPLT FAQ
What does MPLT do?
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California and currently employs 109 full-time employees. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
Can you provide the latest stock price for MAPLIGHT THERAPEUTICS INC?
The current stock price of MPLT is 27.62 USD. The price decreased by -2.54% in the last trading session.
What is the dividend status of MAPLIGHT THERAPEUTICS INC?
MPLT does not pay a dividend.
What is the ChartMill technical and fundamental rating of MPLT stock?
MPLT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for MPLT stock?
MAPLIGHT THERAPEUTICS INC (MPLT) currently has 109 employees.
What is the outstanding short interest for MAPLIGHT THERAPEUTICS INC?
The outstanding short interest for MAPLIGHT THERAPEUTICS INC (MPLT) is 7.2% of its float.